MHC-I genotype and tumor mutational burden predict response to immunotherapy
Abstract Background Immune checkpoint blockade (ICB) with antibodies inhibiting cytotoxic T lymphocyte-associated protein-4 (CTLA-4) and programmed cell death protein-1 (PD-1) (or its ligand (PD-L1)) can stimulate immune responses against cancer and have revolutionized the treatment of tumors. The i...
Main Authors: | Aaron M. Goodman, Andrea Castro, Rachel Marty Pyke, Ryosuke Okamura, Shumei Kato, Paul Riviere, Garrett Frampton, Ethan Sokol, Xinlian Zhang, Edward D. Ball, Hannah Carter, Razelle Kurzrock |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-05-01
|
Series: | Genome Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13073-020-00743-4 |
Similar Items
-
Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy
by: Timothy V. Pham, et al.
Published: (2020-08-01) -
Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma
by: Elena Shklovskaya, et al.
Published: (2020-11-01) -
MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
by: Elena Shklovskaya, et al.
Published: (2021-06-01) -
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
by: Zijun Y. Xu-Monette, et al.
Published: (2017-12-01) -
Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy
by: Marilina García-Aranda, et al.
Published: (2019-05-01)